128 related articles for article (PubMed ID: 19088531)
41. Weekly paclitaxel in heavily pretreated ovarian cancer patients: does this treatment still provide further advantages?
Miolo G; Bidoli E; Lombardi D; Santeufemia DA; Capobianco G; Dessole F; Scalone S; Spazzapan S; Sorio R; Tabaro G; Veronesi A
Arch Gynecol Obstet; 2012 Feb; 285(2):499-503. PubMed ID: 21735184
[TBL] [Abstract][Full Text] [Related]
42. [Scleroderma-like skin changes following administration of paclitaxel for the treatment of ovarian carcinoma].
Eisenbeilss C; Weizel J; Wolff H
J Dtsch Dermatol Ges; 2003 Jun; 1(6):468-70. PubMed ID: 16295141
[TBL] [Abstract][Full Text] [Related]
43. Limited cutaneous systemic sclerosis induced by paclitaxel in a patient with breast cancer.
Kawakami T; Tsutsumi Y; Soma Y
Arch Dermatol; 2009 Jan; 145(1):97-8. PubMed ID: 19153362
[No Abstract] [Full Text] [Related]
44. [Experience in first-line chemotherapy with paclitaxel for the treatment of ovarian carcinomas].
Pete I; Szánthó A; Mayer A; Thurzó L; Pulay T
Orv Hetil; 2003 May; 144(19):919-24. PubMed ID: 12809068
[TBL] [Abstract][Full Text] [Related]
45. A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): a Gynecologic Oncology Group Study.
Sabbatini P; Sill MW; O'Malley D; Adler L; Secord AA;
Gynecol Oncol; 2008 Dec; 111(3):455-60. PubMed ID: 18829087
[TBL] [Abstract][Full Text] [Related]
46. [Second-line chemotherapy with paclitaxel for ovarian cancer].
Lehoczky O; Bagaméri A; Udvary J; Pulay T
Orv Hetil; 2001 Oct; 142(42):2299-301. PubMed ID: 11760646
[TBL] [Abstract][Full Text] [Related]
47. Association between paclitaxel and necrotic pancreatitis.
McMahon MA; Kearns G; McCaffrey J; Grogan L
Ir Med J; 2006 Oct; 99(9):281. PubMed ID: 17144240
[TBL] [Abstract][Full Text] [Related]
48. Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1.
Pecorelli S; Favalli G; Gadducci A; Katsaros D; Panici PB; Carpi A; Scambia G; Ballardini M; Nanni O; Conte P;
J Clin Oncol; 2009 Oct; 27(28):4642-8. PubMed ID: 19704064
[TBL] [Abstract][Full Text] [Related]
49. Neoadjuvant intraperitoneal chemotherapy with paclitaxel for the radical surgical treatment of peritoneal carcinomatosis in ovarian cancer: a prospective pilot study.
Muñoz-Casares FC; Rufián S; Arjona-Sánchez Á; Rubio MJ; Díaz R; Casado Á; Naranjo Á; Díaz-Iglesias CJ; Ortega R; Muñoz-Villanueva MC; Muntané J; Aranda E
Cancer Chemother Pharmacol; 2011 Jul; 68(1):267-74. PubMed ID: 21499894
[TBL] [Abstract][Full Text] [Related]
50. Pharmacoeconomic profile of paclitaxel as a first-line treatment for patients with advanced ovarian carcinoma. A lifetime cost-effectiveness analysis.
Messori A; Cecchi M; Becagli P; Trippoli S
Cancer; 1997 Jun; 79(11):2264-6. PubMed ID: 9179077
[No Abstract] [Full Text] [Related]
51. Effect of paclitaxel administration on P wave duration and dispersion.
Barutcu I; Sezgin AT; Gullu H; Esen AM; Ozdemir R
Clin Auton Res; 2004 Feb; 14(1):34-8. PubMed ID: 15045599
[TBL] [Abstract][Full Text] [Related]
52. Interaction between paclitaxel and warfarin.
Thompson ME; Highley MS
Ann Oncol; 2003 Mar; 14(3):500. PubMed ID: 12598362
[No Abstract] [Full Text] [Related]
53. Acute non-ST elevation myocardial infarction following paclitaxel administration for ovarian carcinoma: a case report and review of literature.
Shah K; Gupta S; Ghosh J; Bajpai J; Maheshwari A
J Cancer Res Ther; 2012; 8(3):442-4. PubMed ID: 23174732
[TBL] [Abstract][Full Text] [Related]
54. Glaucoma and paclitaxel.
De Giorgi U; Acciarri R; Fiorentini G; Rosti G; Marangolo M
Lancet; 2000 Jan; 355(9199):231. PubMed ID: 10675141
[No Abstract] [Full Text] [Related]
55. Cutaneous fixed drug eruption to paclitaxel; a case report.
Baykal C; Erkek E; Tutar E; Yüce K; Ayhan A
Eur J Gynaecol Oncol; 2000; 21(2):190-1. PubMed ID: 10843484
[TBL] [Abstract][Full Text] [Related]
56. Acute myocardial infarction following paclitaxel administration for ovarian carcinoma.
Laher S; Karp SJ
Clin Oncol (R Coll Radiol); 1997; 9(2):124-6. PubMed ID: 9135899
[TBL] [Abstract][Full Text] [Related]
57. Paclitaxel-related dermatological problems: Not only alopecia occurs.
Su MH; Chen GY; Lin JH; Lee HH; Chung KC; Wang PH
Taiwan J Obstet Gynecol; 2019 Nov; 58(6):877-879. PubMed ID: 31759547
[TBL] [Abstract][Full Text] [Related]
58. [Preventing paclitaxel-induced toxicity by reducing glutathione].
Xiong J; Hu J; Zhou L; Zhang L
Zhonghua Gan Zang Bing Za Zhi; 2014 Jan; 22(1):71. PubMed ID: 24754090
[No Abstract] [Full Text] [Related]
59. Successful parenteral desensitization to paclitaxel.
Essayan DM; Kagey-Sobotka A; Colarusso PJ; Lichtenstein LM; Ozols RF; King ED
J Allergy Clin Immunol; 1996 Jan; 97(1 Pt 1):42-6. PubMed ID: 8568136
[TBL] [Abstract][Full Text] [Related]
60. Taxol.
Lancet; 1992 Jun; 339(8807):1447-8. PubMed ID: 1351131
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
